EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
Neuro-Oncology · 04.05.2023 · 25 (5) · 813-826
DOI: 10.1093/neuonc/noad008 ↗Kurz gefasst
Leitlinie in der Zeitschrift Neuro-Oncology, online erschienen am 12.01.2023. Verfasst von David Capper und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, …. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Glioma. Die Arbeit wurde bisher 118-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The mainstay of treatment for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied. Despite that, there is increasing use of advanced molecular diagnostics that identify potential targets, and tumor-agnostic regulatory approvals on targets also present in CNS tumors have been granted. This raises the question of when and for which targets it is meaningful to test in adult patients with CNS tumors. This evidence-based guideline reviews the evidence available for targeted treatment for alterations in the RAS/MAPK pathway (BRAF, NF1), in growth factor receptors (EGFR, ALK, fibroblast growth factor receptor (FGFR), neurotrophic tyrosine receptor kinase (NTRK), platelet-derived growth factor receptor alpha, and ROS1), in cell cycle signaling (CDK4/6, MDM2/4, and TSC1/2) and altered genomic stability (mismatch repair, POLE, high tumor mutational burden (TMB), homologous recombination deficiency) in adult patients with gliomas, glioneuronal and neuronal tumors. At present, targeted treatment for BRAF p.V600E alterations is to be considered part of the standard of care for patients with recurrent gliomas, pending regulatory approval. For approved tumor agnostic treatments for NTRK fusions and high TMB, the evidence for efficacy in adult patients with CNS tumors is very limited, and treatment should preferably be given within prospective clinical registries and trials. For targeted treatment of CNS tumors with FGFR fusions or mutations, clinical trials are ongoing to confirm modest activity so far observed in basket trials. For all other reviewed targets, evidence of benefit in CNS tumors is currently lacking, and testing/treatment should be in the context of available clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Institute of Neuropathology and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Heinrich Heine University, Medical Faculty University Hospital Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
- Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands.
- Institute of Neurology (Edinger Institute), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
- German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID-Profile: David Capper, Leonille Schweizer, Michael Weller, Simone P Niclou, Philipp Euskirchen, Christine Haberler, Sebastian Brandner, Ghazaleh Tabatabai, Felix Sahm, Matthias Preusser, Martin J van den Bent
Zitieren
APA
Capper, D., Reifenberger, G., French, P. J., Schweizer, L., Weller, M., Touat, M., Niclou, S. P., Euskirchen, P., Haberler, C., Hegi, M. E., Brandner, S., Le Rhun, E., Rudà, R., Sanson, M., Tabatabai, G., Sahm, F., Wen, P. Y., Wesseling, P., Preusser, M., & van den Bent, M. J. (2023). EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology, 25(5), 813-826. https://doi.org/10.1093/neuonc/noad008
Vancouver
Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M, et al. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology. 2023;25(5):813-826. doi:10.1093/neuonc/noad008
BibTeX
@article{Capper2023,
author = {Capper, David and Reifenberger, Guido and French, Pim J and Schweizer, Leonille and Weller, Michael and Touat, Mehdi and Niclou, Simone P and Euskirchen, Philipp and Haberler, Christine and Hegi, Monika E and Brandner, Sebastian and Le Rhun, Emilie and Rudà, Roberta and Sanson, Marc and Tabatabai, Ghazaleh and Sahm, Felix and Wen, Patrick Y and Wesseling, Pieter and Preusser, Matthias and van den Bent, Martin J},
title = {EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {5},
pages = {813--826},
doi = {10.1093/neuonc/noad008}
}
EUVIMED